earnings
confidence high
sentiment positive
materiality 0.70
Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M
Amphastar Pharmaceuticals, Inc.
- Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.
- Full-year net revenues $437.8M vs $349.8M in 2020; GAAP net income $62.1M vs $1.4M.
- Adjusted non-GAAP diluted EPS $0.42 for Q4 and $1.37 for full year.
- CEO cites continued growth of higher-margin products and expects pipeline milestones in 2022.